In contrast, ICC mandates the evidence of multi-hit TP53 loss for cases with 0–9% blasts, but single TP53mut VAF ≥ 10% is sufficient to designate MDS/AML and AML as TP53mut MN. This evidence concerns the gene TP53 and acute myeloid leukemia.